Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Serotonin Reuptake Inhibitor Withdrawal

Coupland, Nick J., Bell, Caroline J., Potokar, John P. · 1996 · Journal of Clinical Psychopharmacology

Abstract

We studied reported withdrawal symptoms in a retrospective chart review of 352 patients treated in an outpatient clinic with the nonselective serotonin reuptake inhibitor clomipramine or with one of the selective serotonin reuptake inhibitors (SSRIs), fluoxetine, fluvoxamine, paroxetine, or sertraline. In 171 patients who were supervised during medication tapering and discontinuation, the most common symptoms were dizziness, lethargy, paresthesia, nausea, vivid dreams, irritability, and lowered mood. When patients with at least one qualitatively new symptom were defined as cases, these symptoms occurred significantly more frequently in patients who had been treated either with one of the shorter half-life SSRIs, fluvoxamine or paroxetine (17.2%), or with clomipramine (30.8%), than in patients taking one of the SSRIs with longer half-life metabolites, sertraline or fluoxetine (1.5%). The rate was not significantly different between the different shorter half-life treatments. Cases treated with fluvoxamine or paroxetine had received a significantly longer period of treatment (median 28 weeks) than noncases (16 weeks), but there were no significant associations with age or with diagnostic grouping. There was a trend toward an association with male sex. The majority of cases occurred despite slowly tapered withdrawal. Symptoms persisted for up to 21 days (mean = 11.8 days) after onset. These symptoms were relieved within 24 hours by restarting the medication, but were not relieved by benzodiazepines or by moclobemide. A role has been suggested for serotonin in coordinating sensory and autonomic function with motor activity. We suggest that this may lead to useful hypotheses about the pathophysiology of withdrawal symptoms from serotonin reuptake inhibitors.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004714-199610000-00003

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 25 references

Research works printed but not linked: 9

  1. Stoukides, 1991, Am J Psychiatry, 148, 1263
  2. Black, 1993, J Clin Psychiatry, 54, 146
  3. 1993, harmacovigilance, 19, 1
  4. Louie, 1994, Am J Psychiatry, 151, 450
  5. Debattista, 1995, Am J Psychiatry, 152, 1235
  6. Einbinder, 1995, Am J Psychiatry, 152, 1235
  7. Frost, 1995, Am J Psychiatry, 152, 810
  8. Pyke, 1995, Am J Psychiatry, 152, 149
  9. Richelson, 1984, J Pharmacol Exp Ther, 230, 94

Cited by

See all 304

Metadata

Authors
Coupland, N. J., Bell, C. J., & Potokar, J. P.
Affiliations
University of Alberta (CA)
Venue
Journal of Clinical Psychopharmacology
Published
1996-10
Volume
16
Issue
5
Pages
356-362
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2038826787
Cited by
303
References
25
Citations by year
2026: 2 · 2025: 6 · 2024: 6 · 2023: 2 · 2022: 5 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 7 · 2017: 5 · 2016: 7 · 2015: 5 · 2014: 4 · 2013: 9 · 2012: 10
FWCI
21.48
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
selective serotonin reuptake inhibitors, clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, drug discontinuation, medication tapering, elimination half-life, withdrawal symptoms, benzodiazepines, moclobemide, serotonin
MeSH terms
Adolescent, Adult, Age Factors, Clomipramine, Dizziness, Female, Humans, Male, Middle Aged, Paresthesia, Retrospective Studies, Sex Factors, Substance Withdrawal Syndrome, 1-Naphthylamine, Fluvoxamine, Selective Serotonin Reuptake Inhibitors, Paroxetine, Sertraline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serotonin Reuptake Inhibitor Withdrawal. https://app.cochat.ai/papers/10.1097/00004714-199610000-00003
The paper
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996). Serotonin Reuptake Inhibitor Withdrawal. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199610000-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.